EGFR and cancer: Both NSC777205 and NSC777207 exhibited high similarity with gefitinib and crizotinib, known clinical EGFR and c-MET inhibitors, respectively, in terms of common interacting residues with EGFR and c-MET and similar binding affinities with EGFR, suggesting that both NSC777205 and NSC777207 could be as promising as gefitinib and crizotinib at inhibiting EGFR and c-MET, serving as potential dual targets and thus superseding the strength of individual clinical drugs in arresting cancer proliferation and aggressiveness for which EGFR and c-MET are implicated.